바이오 제염 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the bio decontamination market size was valued at USD 247.34 million in 2025 and estimated to grow from USD 266.1 million in 2026 to reach USD 383.5 million by 2031, at a CAGR of 7.58% during the forecast period (2026-2031).

This report is Segmented by Product and Service (Equipment, Services, Consumables), by Agent Type (Hydrogen Peroxide, Chlorine Dioxide, and More), by Technology (Vaporized Hydrogen Peroxide, Gas Plasma, and More), by End User (Pharmaceutical and Medical-Device Manufacturing Companies. Hospitals and Healthcare Facilities, and More), by Geography (North America, Europe, Asia-Pacific, and More).

Global Bio Decontamination Market Trends and Insights

Rising Incidence of Hospital-Acquired Infections

Hospital-acquired infections affect millions of patients each year, with German facilities losing EUR 1,000 per avoidable case, which places direct financial pressure on administrators to upgrade environmental hygiene. The emergence of Klebsiella pneumoniae ST307, tolerant of 70% of standard biocides, underscores the need for more potent decontamination technologies. Proposed USD 240 million cuts to the US Hospital Preparedness Program would reduce staffing for manual cleaning, which in turn encourages automated no-touch systems that maintain compliance with lean personnel models. The Joint Commission's 2024 standards emphasize surface cleaning in patient areas, sparking immediate demand for mobile vaporized hydrogen peroxide generators. In the United Kingdom, NHS England's 2025 cleanliness benchmarks set rigorous environmental targets that require validated bio decontamination solutions. The CDC's updated surface disinfection guidance positions environmental services as a core element of safety culture, making automated bio decontamination a strategic investment.

Growing Number of Surgical Procedures Worldwide

Global surgical volumes continue to climb, and each procedure generates multiple instrument reprocessing cycles that rely on dependable decontamination. STERIS reported 14% healthcare service revenue growth in fiscal 2024, largely attributed to higher operating-room throughput. Adoption of minimally invasive techniques raises demand for low-temperature sterilization that protects delicate polymeric components. The FDA's clearance of vaporized hydrogen peroxide for 3D-printed surgical guides removes a regulatory barrier for personalized implants. Outpatient centers, which hinge on rapid instrument turnover, are installing compact units that finish cycles in under 30 minutes, thus cutting patient wait times. Ageing populations in developed countries guarantee continuing growth in elective interventions, while emerging markets accelerate surgery installations to meet basic healthcare needs. The proliferation of robotic surgery platforms increases the volume and complexity of reusable tools, strengthening the outlook for the bio decontamination market.

High Capital Cost of Advanced Equipment

A hydrogen peroxide vapor system can list at EUR 50,000, whereas aerosolized alternatives often cost under EUR 10,000, challenging small hospitals that operate on modest capital budgets. The transition away from ethylene oxide further inflates budgets by triggering validation studies and workforce retraining. Healthcare administrators must prioritize among competing investments, and decontamination may rank below imaging equipment when funds are tight. Validation for specialty products such as prefilled syringes adds laboratory costs that raise the total cost of ownership beyond sticker price. Emerging markets face currency volatility that magnifies imported capital-equipment expenses. Finally, complex systems need skilled maintenance, and a shortage of local technicians can extend downtime and increase lifetime costs.

Other drivers and restraints analyzed in the detailed report include:

1. Stringent Sterility Regulations in Pharma Manufacturing
2. Increasing Outsourcing of Bio Decontamination Services
3. Budgetary Constraints in Healthcare Facilities

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Equipment captured 48.33% of 2025 revenue in the bio decontamination market, underscoring how capital assets remain the backbone of contamination-control strategies. Large pharmaceutical plants adopt fixed vaporized hydrogen peroxide chambers to replace aging ethylene oxide units, spurred by the FDA's 2024 Category A recognition that lowered regulatory uncertainty. Service revenues grow as hospitals and contract manufacturers embrace leasing models that bundle preventive maintenance and consumable supply, reducing up-front expenditure. Consumables, including hydrogen peroxide cartridges and single-use delivery nozzles, are growing at a 9.10% CAGR because higher cycle frequencies are mandated by stricter cleaning protocols. Integrated asset-as-a-service agreements, which guarantee uptime and include remote performance monitoring, are reshaping vendor-customer relationships by shifting risk toward suppliers. The bio decontamination market continues to see OEMs diversify into managed-service tiers that provide validation support and regulatory documentation. Over the forecast horizon, equipment suppliers will concentrate on modular systems that fit within pre-fabricated cleanrooms, cutting installation time for greenfield biologics facilities. Service providers are also incorporating digital twins that simulate chamber performance, which helps operators plan maintenance windows without disrupting production. Sustainability metrics drive interest in reclaim systems that reduce hydrogen peroxide consumption, ensuring future growth in both consumable and upgrade kits.

Consumables benefit from varied end-user segments, including pharmacies that run daily instrument cycles and biosafety laboratories that decontaminate high-risk agents. The increase in turnaround frequency directly feeds volume demand for single-use spray heads and catalyzers, making consumables the fastest contributor to incremental revenue. In emerging geographies, distributors bundle consumables with remote validation software to overcome staff shortages, allowing facilities to meet EU GMP standards without owning advanced analytic tools. The bio decontamination market is therefore experiencing a gradual shift in revenue mix toward recurring streams, a trend likely to accelerate as more hospitals outsource non-core processes. Over the next five years, equipment renewals will peak as ethylene oxide is phased down, after which consumable and service revenue will form the bulk of vendor cash flow. Overall, the combined trajectory of equipment and consumables keeps the bio decontamination market on a stable multi-year expansion path.

Hydrogen peroxide retained 50.72% bio decontamination market share in 2025, supported by decades of efficacy data and broad regulatory acceptance. Its decomposition into water and oxygen aligns with corporate sustainability goals, encouraging adoption across pharmaceutical, medical device, and hospital settings. Enhanced efficacy against resistant spores sustains its popularity, and innovation in plasma-activated water boosts kill rates while retaining material compatibility. However, peracetic acid, posting an 8.31% CAGR, is gaining ground due to environmental credentials and strong performance in surface applications, including advanced oxidation for wastewater treatment that aligns with zero-liquid-discharge policies. Chlorine dioxide maintains relevance for whole-facility fumigation, particularly during refurbishments when large volumes must be treated quickly. Nitrogen dioxide sterilization, operating at room temperature and low concentrations, shows promise for complex combination products that cannot tolerate heat, radiation, or high humidity. The others category, featuring ozone and hypochlorous acid, caters to niche applications yet faces stability issues limiting mainstream use.

Emerging agents battle established incumbents on the axes of cycle time, residue, and material compatibility. Peracetic-acid blends combined with surfactants achieve shorter contact times, making them attractive for high-throughput hospitals. Research in plasma-enhanced hydrogen peroxide underscores the agent's flexibility as operators can dial concentrations to match bioburden without harming sensitive plastics, extending its leadership position. Combination chemistries such as chlorine dioxide with UV-C aim to deliver rapid kill in high-volume instrument reprocessing units, although cost remains a barrier. Future market share shifts will hinge on regulatory acceptance for novel agents and demonstration of consistent efficacy in real-world conditions. Vendors that can validate multi-agent platforms gain a competitive edge, appealing to facilities that must decontaminate diverse substrates under a single quality system. Overall, intense innovation ensures that the bio decontamination market will remain technologically dynamic, with hydrogen peroxide's dominance challenged but not yet displaced.

Complete Report Scope:

• By Product and Service
  • Equipment
  • Services
  • Consumables
• By Agent Type
  • Hydrogen Peroxide
  • Chlorine Dioxide
  • Peracetic Acid
  • Nitrogen Dioxide
  • Others
• By Technology
  • Vaporized Hydrogen Peroxide (VHP)
  • Hybrid Hydrogen Peroxide (HHP)
  • Gas Plasma
  • Others
• By End User
  • Pharmaceutical and Medical-Device Manufacturing Companies
  • Life-Sciences and Biotechnology Research Organizations
  • Hospitals and Healthcare Facilities
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 41.96% revenue in 2025, anchored by the United States where FDA guidance and ANSI/AAMI ST24 revisions spur steady equipment upgrades. Federal recognition of vaporized hydrogen peroxide as Category A reduced regulatory friction, enabling faster procurement cycles for device manufacturers. Canada adopts similar frameworks, while Mexico's grow-your-own drug-manufacturing initiatives add base-load demand for mid-tier chambers. The region also benefits from consolidation among hospital systems, which standardize equipment lists and negotiate multi-site service contracts, supporting predictable pull-through of consumables.

Asia-Pacific is the fastest-growing territory, posting a 9.98% CAGR to 2031, driven by Chinese and Indian biologics expansions, as well as supply-chain realignments prompted by the 2024 US Biosecure Act. Indian CDMOs, which handled USD 15.63 billion work orders in 2023, must now demonstrate US-equivalent sterility compliance, propelling orders for hybrid hydrogen peroxide suites. Japan and South Korea allocate national R&D budgets toward biopharmaceutical innovation, fueling decontamination spend in pilot and commercial facilities. Australia's Therapeutic Goods Administration demands rigorous sterility dossier submissions, encouraging early adoption of AI-infused validation software bundled with chambers.

Europe posts stable mid-single-digit growth, heavily influenced by Annex 1 and Annex 2 enforcement. Germany's pharmaceutical cluster around Frankfurt invests in advanced airborne decontamination for continuous production lines, while the United Kingdom's biotech hubs leverage venture funding to install modular cleanrooms equipped with VHP generators. Southern European nations catch up on infection-control modernizations, focusing on public hospital refurbishments where chlorine dioxide fumigation reduces refurbishment downtime. The Middle East and Africa region remains nascent but benefits from GCC government programs targeting premium healthcare infrastructure. South America, led by Brazil, gradually adopts hydrogen peroxide systems to align with WHO infection-prevention goals, though fiscal constraints slow rollout. The geographic spread ensures multi-vector growth, safeguarding the long-term trajectory of the bio decontamination market.

1. Steris plc
2. Ecolab (Bioquell)
3. TOMI Environmental Solutions
4. Getinge
5. ClorDiSys Solutions Inc.
6. Fedegari Autoclavi SpA
7. Amira SRL
8. Howorth Air Technology Ltd
9. JCE Biotechnology
10. Zhejiang Tailin Bioengineering Co. Ltd
11. Noxilizer Inc.
12. Stryker (Cantel Medical)
13. Curis System
14. Solvay SA (Peroxides)
15. Arkema Peroxides
16. Evonik Industries
17. Johnson & Johnson (ASP)
18. 3M

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising incidence of hospital-acquired infections
  • 4.2.2 Growing number of surgical procedures worldwide
  • 4.2.3 Stringent sterility regulations in pharma manufacturing
  • 4.2.4 Increasing outsourcing of bio-decontamination services
  • 4.2.5 Adoption in ATMP & cell-gene therapy cleanrooms (under-the-radar)
  • 4.2.6 Rapid-turnaround biothreat response in aerospace & defense sites (under-the-radar)
• 4.3 Market Restraints
  • 4.3.1 High capital cost of advanced equipment
  • 4.3.2 Budgetary constraints in healthcare facilities
  • 4.3.3 Material-compatibility & safety concerns with chemical agents
  • 4.3.4 Lack of standardized validation for large biologics suites (under-the-radar)
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product and Service
  • 5.1.1 Equipment
  • 5.1.2 Services
  • 5.1.3 Consumables
• 5.2 By Agent Type
  • 5.2.1 Hydrogen Peroxide
  • 5.2.2 Chlorine Dioxide
  • 5.2.3 Peracetic Acid
  • 5.2.4 Nitrogen Dioxide
  • 5.2.5 Others
• 5.3 By Technology
  • 5.3.1 Vaporized Hydrogen Peroxide (VHP)
  • 5.3.2 Hybrid Hydrogen Peroxide (HHP)
  • 5.3.3 Gas Plasma
  • 5.3.4 Others
• 5.4 By End User
  • 5.4.1 Pharmaceutical and Medical-Device Manufacturing Companies
  • 5.4.2 Life-Sciences and Biotechnology Research Organizations
  • 5.4.3 Hospitals and Healthcare Facilities
  • 5.4.4 Others
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Steris plc
  • 6.3.2 Ecolab (Bioquell)
  • 6.3.3 TOMI Environmental Solutions Inc.
  • 6.3.4 Getinge AB
  • 6.3.5 ClorDiSys Solutions Inc.
  • 6.3.6 Fedegari Autoclavi SpA
  • 6.3.7 Amira SRL
  • 6.3.8 Howorth Air Technology Ltd
  • 6.3.9 JCE Biotechnology
  • 6.3.10 Zhejiang Tailin Bioengineering Co. Ltd
  • 6.3.11 Noxilizer Inc.
  • 6.3.12 Stryker (Cantel Medical)
  • 6.3.13 Curis System
  • 6.3.14 Solvay SA (Peroxides)
  • 6.3.15 Arkema Peroxides
  • 6.3.16 Evonik Industries AG
  • 6.3.17 Johnson & Johnson (ASP)
  • 6.3.18 3M Healthcare

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment